comparemela.com

Latest Breaking News On - Integrated networks - Page 5 : comparemela.com

Implementation of isoniazid preventive therapy in southern Lima, Peru: an analysis of health center characteristics

Background Tuberculosis (TB) prevention through the use of preventive treatment is a critical activity in the elimination of TB. In multiple settings, limited staffing has been identified as a barrier to managing preventive treatment for TB contacts. This study aims to determine how health center staffing, service type, and TB caseload affects implementation of isoniazid preventive therapy (IPT) for TB contacts in southern Lima. Methods We conducted an ecological study in 2019 in southern Lima, Peru. Through the review of medical records, we identified contacts of TB patients who initiated IPT during 2016–2018, and who were 0–19 years old, the age group eligible for IPT according to Peruvian guidelines. We assessed bivariate associations between health center characteristics (numbers of physicians and nurses, types of services available, annual TB caseload) and IPT initiation and completion using binomial logistic regression.

Astonishing engineering and meticulous restoration sees CPO reopen

Astonishing engineering and meticulous restoration sees CPO reopen
livenews.co.nz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from livenews.co.nz Daily Mail and Mail on Sunday newspapers.

MDC Partners Inc Reports Results For The Three And Twelve Months Ended December 31, 2020

Guides 7-9% Revenue Growth in 2021 FOURTH QUARTER & 2020 HIGHLIGHTS: Revenue of $328.2 million in the fourth quarter versus $382.0 million in the prior year period, a decline of 14.1%; and $1.20 billion in 2020 versus $1.42 billion in the prior year, a decline of 15.3%. Sequential revenue growth of 15.8% from the third quarter of 2020. Organic revenue declined 13.7% in the fourth quarter and 13.9% in 2020. Net loss attributable to MDC Partners Inc. common shareholders was $243.2 million (inclusive of principally non-cash impairment and other charges of $96.4 million and a $130 million non-cash income tax valuation allowance) in 2020 versus a net loss of $17.6 million in the prior year. Adjusted EBITDA of $177.3 million in 2020 versus $174.2 million in the prior year, an increase of 1.8%. Adjusted EBITDA Margin of 14.8% in 2020, increasing 250 basis points from 12.3% in the prior year.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.